Navigation Links
Vandetanib in Medical News

Enrollment completed in 2 pivotal phase III studies of the investigational cancer drug vandetanib

WILMINGTON, Del., March 12, 2008 AstraZeneca (NYSE: AZN) announced today that it has completed patient enrollment in two pivotal Phase III studies for vandetanib, the companys investigational, once-daily oral anti-cancer drug, for the second-line treatment of non-small cell lung cancer (NSCLC). T...

Advanced targeted therapies effective as first-line treatment for lung cancer

...m PT in Moscone West, Room 2001-2005, Level 2. vandetanib PLUS DOCETAXEL VERSUS DOCETAXEL AS SECOND-LINE TRE...IND PHASE III TRIAL (ZODIAC) (ABSTRACT # C2.2) vandetanib is an orally administered medication that targets ...eptors are targeted separately by other drugs, but vandetanib is the first drug designed to target both. In ...

AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer

...dicines Agency (EMEA) for an investigational drug, vandetanib 100 mg for use in combination with chemotherapy fo...ical studies evaluating the safety and efficacy of vandetanib 100 mg in combination with chemotherapy. Pending ...l be marketed as ZACTIMA(TM). Evaluation of vandetanib is ongoing, as monotherapy or in combination with ...

Vandetanib shows clinical benefit when combined with docetaxel for lung cancer

...III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients wi...me day take a group that's receiving docetaxel and vandetanib and see them do even better. We're not there yet, ... In terms of side effects, patients who received vandetanib experienced more diarrhea, rash and neutropenia. H...

Drug therapy reduces neuroblastoma tumor growth in pre-clinical investigation

...day in a special platform session. "By itself, vandetanib inhibited tumor growth by two-thirds and decreased... the impact was even greater on tumor growth." vandetanib blocks a family of endothelial growth factors and ...tion. This trial is the first in the world to test vandetanib in children. Zage says in addition to the pedia...

Vandetanib Study Enters Third Phase

... 20 sites. The patients who have a recorded a case of locally advanced or metastatic non-small cell lung cancer will be given the once-daily drug vandetanib in addition to pemetrexed, as a second line treatment. Says Medical Science Director for Vandetanib, Dr Peter Langmuir, 'After treatment failure w...
Vandetanib in Medical Technology

Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology

ORLANDO, Fla., May 30 Data from the Phase III ZODIAC study in advanced non-small cell lung cancer patients, with the investigational drug vandetanib, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Orlando. Results show that the study met its primary endpoint, d...

AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer

WILMINGTON, Del., Nov. 30 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that it has completed enrollment of patients in the ZEST (ZACTIMA Efficacy Study versus Tarceva) study, the first of four Phase III trials for the investigational once-daily oral anti-cancer drug vandet...

Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

- Phase III trials now underway to evaluate vandetanib as second-line NSCLC treatment in combination with docetaxel - WILMINGTON, Del., Sept. 20 /PRNewswire/ -- Results published today in the Journal of Clinical Oncology(1) show that the AstraZeneca investigational once-daily oral ...
Vandetanib in Biological Technology

AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)

WILMINGTON, Del., March 12 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that it has completed patient enrollment in two pivotal Phase III studies for vandetanib, the company's investigational, once-daily oral anti-cancer drug, for the second-line treatment of non-small cel...
Other Tags
(Date:7/13/2014)... HealthDay Reporter FRIDAY, July ... sensor for people with diabetes is being developed to measure ... researchers report. Scientists at Brown University in Providence, R.I., ... It uses light, metal and a special enzyme that changes ... diabetics have to prick their fingers to draw blood to ...
(Date:7/13/2014)... 13, 2014 Recently, 2014QuinceaneraDresses.com, the ... unveiled its new range of gorgeous Quinceanera ... the demand for elegant Quinceanera outfits is huge. ... items. All the company’s newly released dresses are ... are all elegant and vivid. , It ...
(Date:7/13/2014)... Texas (PRWEB) July 13, 2014 Epidemiologists ... aGVHD in the 6MM, from 8,062 diagnosed incident cases ... at an Annual Growth Rate (AGR) of 4.35%, during ... the highest number of diagnosed incident cases of aGVHD ... Spain will have the lowest number of diagnosed incident ...
(Date:7/13/2014)... 13, 2014 Wright & Schulte LLC ... been scheduled in July of 2015, in U.S. District ... are in the discovery process in the South ... is presiding over the multidistrict litigation (MDL). The complaints ... of individuals who allege that they took the statin ...
(Date:7/13/2014)... Hope Palliative & Hospice Care announced today that they ... Tamarack Senior Living Community in Palatine, IL. The group, called ... 3rd Wednesdays of every month. This group will begin ... at 55 S. Greeley St. Palatine, IL 60067. It ... cost for the group. , “A grief support group ...
Breaking Medicine News(10 mins):Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2
(Date:7/10/2014)... 2014 NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused ... Gino Pereira was interviewed on July 1 st ... Florida . Mr. Pereira discusses the company,s next generation ... and how the Wocket™ aims to replace a traditional wallet ... Cedric Harris tells Gino he has never heard of ...
(Date:7/10/2014)... DUBLIN , July 3, 2014 ... the addition of the "Global Gesture Recognition ... Market - Forecasts to 2020" report to ... Global Gesture Recognition & Touch-Less Sensing ... been around for a while, but the companies ...
(Date:7/10/2014)... According to a new market ... Systems Market Global Forecast, Market Share, Size, Growth and ... Control systems market was valued at USD 15,406.1 million ... CAGR of 12.6% from 2014 to 2019, to reach ... Browse the full Electronic Access Control Systems ...
Breaking Biology News(10 mins):Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5
Other Contents